Exagen to study autoimmune disease development in COVID-19 patients, shares rise

Exagen

29/03/2021 17:32

** Diagnostic tests provider's  XGN.O  shares rise 2.1% to
$17.96    
    ** XGN says it will collaborate with Emory University on a
new study about the long-term effects of COVID-19 infection in
the development of autoimmune diseases such as lupus and
rheumatoid arthritis  urn:newsml:reuters.com:*:nGNX4JC7v0
    ** CO says study will assess the emergence of automimmune
disease biomarkers in mild to moderate COVID patients, among
several critical patient groups
    ** Stock had gained 33.3% this year as of its last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))